Concurrent chemotherapy

Phase 2

Concurrent chemotherapy is one of 5 therapeutic programs targeting NSCLC (Non-small Cell Lung Cancer). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NSCLC (non-Small Cell Lung Cancer)Recruiting

NSCLC (non-Small Cell Lung Cancer)Phase 2

Recruiting

Competition

Competitive Landscape

4 competitors in NSCLC (non-Small Cell Lung Cancer)

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

1 2

Beyfortus

BeiGene

Phase 2

1 3

Daraxonrasib

Revolution Medicines

Phase 3

1 4

Surufatinib

HHutchison Medipharma Limited

Phase 2

1 5

Concurrent chemotherapy

SSun Yat-sen University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

NSCLC (non-Small Cell Lung Cancer)

NCT07609121

Clinical

Trials by Indication[1]

NSCLC (Non-small Cell Lung Cancer)1 trial

A Randomized Phase 2 Study of Hypofractionated Concurrent Chemoradiotherapy Combined With Tislelizumab and Surufatinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT07609121·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Concurrent chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Concurrent chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Concurrent chemotherapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

NSCLC (Non-small Cell Lung Cancer)1 trial

References

Drug Info

Quick Facts

Related News